Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new re…
Uncategorized
Publication Exclusive: Surgeon details pterygium surgery technique with auto-limbal conjunctival grafting
Pterygium surgery may be required to improve vision or cosmetic appearance or for symptomatic relief, and often it is challenging both intraoperatively and postoperatively. When pterygium and cataract surgeries are staged as two separate procedures, th…
Uncategorized
Research and Markets: Retinal Vein Occlusion Forecast 2015-2025 – Further Insight into the Prevalence of the Subdivided Types of RVO and Identify Patient Segments with High Potential
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/88mccb/epiomic) has announced the addition of the “Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 8 Major Markets 2015-2025” report to their offe…
Rituximab (RTX) Therapy in Patients With Active TAO
Status: Recruiting,
Condition Summary: Ophthalmopathy, Thyroid-Associated
Uncategorized
Dry eye symptoms may be correlated to non-ocular conditions
Dry eye symptoms may be more closely correlated to non-ocular conditions than tear film status, according to a study.The cross-sectional study evaluated 136 patients at the Miami Veterans Affairs eye clinic to assess dry eye symptoms, non-ocular conditions and tear film parameters. Non-ocular conditions consisted of self-reported non-ocular pain, depression and PTSD, while tear film parameters consisted of osmolarity, tear breakup time, corneal staining, Schirmer’s test, eyelid vascularity and meibum quality.
NovaBay Pharmaceuticals Reports 2015 Second Quarter Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three months and six months ended June 30, 2015, and provided a business update. Quarterly and Recent Operational and Financial Highlights Grew sales of Avenova™ Lid and Lash Cleanser by 73% to $806,000 in the second quarter of 2015 ove